# Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

> **NCT01052480** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 98 (actual)

## Conditions studied

- Influenza A
- Influenza B

## Interventions

- **BIOLOGICAL:** Anti-Influenza Immune Plasma
- **DRUG:** Standard Care

## Key facts

- **NCT ID:** NCT01052480
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-11
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2017-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01052480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01052480, "Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01052480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*